enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Rating of “Buy” from Brokerages

enGene Holdings Inc. (NASDAQ:ENGN) has been assigned a consensus recommendation of “Buy” from the seven research firms that are presently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $33.67.

A number of equities research analysts recently issued reports on the company. Oppenheimer reiterated an “outperform” rating and issued a $30.00 price objective on shares of enGene in a research report on Tuesday, September 24th. Morgan Stanley reaffirmed an “overweight” rating and issued a $40.00 price target on shares of enGene in a report on Wednesday, September 11th.

enGene Stock Down 3.8 %

Shares of ENGN opened at $7.63 on Monday. enGene has a twelve month low of $4.42 and a twelve month high of $18.40. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. The business’s 50-day moving average price is $7.63 and its 200-day moving average price is $8.86.

enGene (NASDAQ:ENGN) last posted its earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.05. On average, analysts predict that enGene will post -1.54 earnings per share for the current year.

Insiders Place Their Bets

In other enGene news, CEO Ronald Harold Wilfred Cooper bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average price of $5.70 per share, for a total transaction of $57,000.00. Following the transaction, the chief executive officer now directly owns 10,000 shares in the company, valued at $57,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Growth Opportunities F. Forbion purchased 41,639 shares of the business’s stock in a transaction on Friday, September 27th. The shares were acquired at an average price of $5.97 per share, with a total value of $248,584.83. Following the completion of the transaction, the insider now owns 2,059,459 shares of the company’s stock, valued at approximately $12,294,970.23. This trade represents a 2.06 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 420,965 shares of company stock valued at $2,651,103 over the last 90 days. Insiders own 13.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Janus Henderson Group PLC bought a new stake in enGene in the 1st quarter worth $17,095,000. SR One Capital Management LP purchased a new stake in shares of enGene during the second quarter worth about $4,715,000. Logos Global Management LP grew its stake in shares of enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after purchasing an additional 400,000 shares during the last quarter. Wolverine Asset Management LLC purchased a new position in enGene during the 3rd quarter valued at about $37,000. Finally, Point72 Asset Management L.P. increased its holdings in enGene by 1,410.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after purchasing an additional 619,100 shares during the period. Hedge funds and other institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.